Early Lenalidomide Maintenance to Prevent Relapse of High-Risk MDS and AML Patients with Del(5q) Following Allogeneic HCT - Results of the "LENAMAINT" Trial

被引：2
|
作者：
Sockel, Katja [1 ]
Greiner, Jochen [2 ]
Trenschel, Rudolf [3 ]
Unzicker, Christian [4 ]
Kobbe, Guido [5 ]
Finke, Jurgen [6 ]
Germing, Ulrich [7 ]
Mohr, Brigitte [1 ]
Beelen, Dietrich [8 ]
Ehninger, Gerhard [9 ]
Bornhaeuser, Martin [1 ]
Platzbecker, Uwe [1 ]
机构：
[1] Univ Hosp Dresden, Med Clin & Policlin 1, Dresden, Germany
[2] Univ Ulm, Dept Internal Med 3, D-7900 Ulm, Germany
[3] Univ Hosp, Clin Bone Marrow Transplantat, Essen, Germany
[4] Wuerzburg Univ, Med Ctr, Dept Internal Med 2, Wurzburg, Germany
[5] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany
[6] Univ Freiburg Klinikum, Dept Med 1, Freiburg, Germany
[7] Univ Hosp Dusseldorf, Dusseldorf, Germany
[8] Univ Hosp Essen, Dept Bone Marrow Transplantat, Essen, Germany
[9] Univ Hosp Carl Gustav Carus, Med Clin & Policlin 1, D-01307 Dresden, Germany
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.3060.3060
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：1320 / 1320
页数：1
相关论文
共 50 条
  • [41] Post-Transplant Maintenance With The Deacetylase Inhibitor Panobinostat In Patients With High-Risk AML Or MDS: Results Of The Phase I Part Of The Panobest Trial
    Bug, Gesine
    Burchert, Andreas
    Nicolaus, Kroeger
    Huenecke, Sabine
    Duenzinger, Ulrich
    Wolf, Andrea
    Bader, Peter
    Serve, Hubert
    Ottmann, Oliver G.
    BLOOD, 2013, 122 (21)
  • [42] Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
    Pierre Fenaux
    Aristoteles Giagounidis
    Dominik Selleslag
    Odile Beyne-Rauzy
    Moshe Mittelman
    Petra Muus
    Stephen D. Nimer
    Eva Hellström-Lindberg
    Bayard L. Powell
    Agnes Guerci-Bresler
    Mikkael A. Sekeres
    H. Joachim Deeg
    Consuelo del Cañizo
    Peter L. Greenberg
    Jamile M. Shammo
    Barry Skikne
    Xujie Yu
    Alan F. List
    Journal of Hematology & Oncology, 10
  • [43] Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Selleslag, Dominik
    Beyne-Rauzy, Odile
    Mittelman, Moshe
    Muus, Petra
    Nimer, Stephen D.
    Hellstrom-Lindberg, Eva
    Powell, Bayard L.
    Guerci-Bresler, Agnes
    Sekeres, Mikkael A.
    Deeg, H. Joachim
    del Canizo, Consuelo
    Greenberg, Peter L.
    Shammo, Jamile M.
    Skikne, Barry
    Yu, Xujie
    List, Alan F.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
  • [44] IDENTIFICATION OF BIOMARKERS WHICH COULD PREDICT THE HEMATOLOGICAL RESPONSE OF NON DEL(5Q) LOW-RISK MDS PATIENTS TREATED BY LENALIDOMIDE; THE GFM EXPERIENCE
    Chesnais, V.
    Renneville, A.
    Sardnal, V.
    Delaunay, J.
    Rose, C.
    Stamatoulas, A.
    Beyne-Rauzy, O.
    Fenaux, P.
    Toma, A.
    Drefyus, F.
    Preudhomme, C.
    Kosmider, O.
    Fontenay, M.
    HAEMATOLOGICA, 2014, 99 : 501 - 501
  • [45] Phase 3 Study of Lenalidomide vs Placebo in Non-Transfusion Dependent Low Risk del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 17 - 18
  • [46] Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study
    Ades, Lionel
    Boehrer, Simone
    Prebet, Thomas
    Beyne-Rauzy, Odile
    Legros, Laurence
    Ravoet, Christophe
    Dreyfus, Francois
    Stamatoullas, Aspasia
    Chaury, Marie Pierre
    Delaunay, Jacques
    Laurent, Guy
    Vey, Norbert
    Burcheri, Sara
    Mbida, Rose-Marie
    Hoarau, Natacha
    Gardin, Claude
    Fenaux, Pierre
    BLOOD, 2009, 113 (17) : 3947 - 3952
  • [47] The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study
    Santini, Valeria
    Almeida, Antonio
    Giagounidis, Aristoteles
    Platzbecker, Uwe
    Buckstein, Rena
    Beach, C. L.
    Guo, Shien
    Altincatal, Arman
    Wu, Chengqing
    Fenaux, Pierre
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (02): : 136 - +
  • [48] Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality.
    Fenaux, P.
    Glagounidis, A.
    Selleslag, D. L.
    Beyne-Rauzy, O.
    Mittelman, M.
    Muus, P.
    Knight, R. D.
    Fu, T.
    Hellstrom-Lindberg, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) in AML and Higher Risk MDS with Del 5q. Interim Results of a Phase I/II Study.
    Ades, Lionel
    Stamatoullas, Aspasia
    Raffoux, Emmanuel
    Prebet, Thomas
    Lenain, Pascal
    Guieze, Romain
    Hunault, Mathilde
    Wattel, Eric
    Stalnikiewicz, Laurence
    Bouabdallah, Krimo
    Levy, Vincent
    Vey, Norbert
    Dombret, Herve
    Boehrer, Simone
    Gardin, Claude
    Fenaux, Pierre
    BLOOD, 2009, 114 (22) : 434 - 434
  • [50] Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)
    Almeida, Antonio
    Santini, Valeria
    Croepper, Stefanie
    Jonasova, Anna
    Vey, Norbert
    Giagounidis, Aristoteles
    Hellstrom-Lindberg, Eva
    Mufti, Ghulam J.
    Sanz, Guillermo
    Skikne, Barry
    Hoenekopp, Albert
    Seguy, Francis
    Zhong, Jianhua
    Fenaux, Pierre
    BLOOD, 2015, 126 (23)
12345